(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 March 2023 (30.03.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/046117 A1

(51) International Patent Classification:
*C07D 487/04* (2006.01) *A61P 35/00* (2006.01)
*A61K 31/519* (2006.01)

(21) International Application Number:
PCT/CN2022/121076

(22) International Filing Date:
23 September 2022 (23.09.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2021/119861
23 September 2021 (23.09.2021) CN
PCT/CN2022/096894
02 June 2022 (02.06.2022) CN

(71) Applicants: **3H PHARMACEUTICALS CO., LTD.** [CN/CN]; No.79, 85 Cailun Road, Pudong High-Tech District, Shanghai 201203 (CN). **3H (SUZHOU) PHARMACEUTICALS CO., LTD.** [CN/CN]; Rm 201, Bld B6, Biomedical Industrial Park, No. 218, Xinghu Str., Suzhou, Jiangsu 215123 (CN).

(72) Inventors: **HU, Jingyu**; No.79, 85 Cailun Road, Pudong High-Tech District, Shanghai 201203 (CN). **FU, Xianlei**; No.79, 85 Cailun Road, Pudong High-Tech District, Shanghai 201203 (CN). **LIU, Yanchao**; No.79, 85 Cailun Road, Pudong High-Tech District, Shanghai 201203 (CN). **ZHANG, Zhixiong**; No.79, 85 Cailun Road, Pudong High-Tech District, Shanghai 201203 (CN). **ZHANG, Weibo**; No.79, 85 Cailun Road, Pudong High-Tech District, Shanghai 201203 (CN). **HU, Shaojing**; No.79, 85 Cailun Road, Pudong High-Tech District, Shanghai 201203 (US). **CHEN, Kevin X**; No.79, 85 Cailun Road, Pudong High-Tech District, Shanghai 201203 (US).

(74) Agent: **BEIJING HUIZE INTELLECTUAL PROPERTY LAW LLC**; ZHANG, Jin, A1813, Horizon International Tower, No.6, Zhichun Road, Haidian District, Beijing 100088 (CN).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report (Art. 21(3))*

WO 2023/046117 A1

(54) Title: FGFR INHIBITORS AND METHODS OF USE THEREOF




(I)

(57) Abstract: Provide novel compounds of Formula (I) and pharmaceutical composition, pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, and isomer thereof, useful as FGFR inhibitors to modulate or inhibit the activity of FGFR enzymes. Further relates to, but is not limited to, methods for treating disorders associated with FGFR signaling with the compounds and compositions.